Innoviva (INVA) Revenue (2011 - 2026)
Innoviva's (INVA) quarterly Revenue came in at $98.0 million in Q1 2026, up 10.56% YoY from $88.6 million in Q1 2025, and up 8931.71% on a QoQ basis from $1.1 million in Q4 2025.
Innoviva (INVA) Revenue (2011 - 2026) Analysis & Trends
Innoviva (INVA) has 16 years of Revenue data on file, last reported at $98.0 million in Q1 2026.
- Quarterly Revenue rose 10.56% year-over-year to $98.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $496.1 million (up 8.63% YoY) and the FY2025 annual result came in at $411.3 million, up 14.67% from the prior year.
- Revenue climbed to $98.0 million in Q1 2026, from $1.1 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $296.7 million in Q3 2025 to a low of $1.1 million in Q4 2022.
- A 5-year average of $85.8 million and a median of $4.1 million in 2022 frame the typical range for Revenue.
- Annual changes were most pronounced in 2023 — Revenue plunged 31.18% — and 2025, when it soared 3453.81%.
- Tracing INVA's Revenue over 5 years: stood at $1.1 million in 2022, then jumped by 45.39% to $1.5 million in 2023, then slipped by 19.18% to $1.2 million in 2024, then decreased by 12.15% to $1.1 million in 2025, then soared by 8931.71% to $98.0 million in 2026.
- The last three Revenue figures came in at $98.0 million (Q1 2026), $1.1 million (Q4 2025), and $296.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Innoviva | 1.54 Bn | 968.79 Mn | 90.62 Mn | 119.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 119.59 Mn |
| Mar 31, 2026 | 97.99 Mn |
| Dec 31, 2025 | 1.09 Mn |
| Sep 30, 2025 | 296.72 Mn |
| Jun 30, 2025 | 100.28 Mn |
| Mar 31, 2025 | 88.63 Mn |
| Dec 31, 2024 | 1.24 Mn |
| Sep 30, 2024 | 266.91 Mn |
| Jun 30, 2024 | 99.90 Mn |
| Mar 31, 2024 | 2.49 Mn |
| Dec 31, 2023 | 1.53 Mn |
| Sep 30, 2023 | 224.62 Mn |
| Jun 30, 2023 | 2.83 Mn |
| Mar 31, 2023 | 1.85 Mn |
| Dec 31, 2022 | 1.05 Mn |
| Sep 30, 2022 | 265.54 Mn |
| Jun 30, 2022 | 4.11 Mn |
| Mar 31, 2022 | 2.23 Mn |
| Dec 31, 2021 | 989,000.00 |
| Sep 30, 2021 | 284.19 Mn |